Zapnometinib treatment and influenza A virus infection modulate the HLA class I ligandome in human lung adenocarcinoma cells
By
Hazem Hamza
Michael Ghosh
Hans-Georg Rammensee
Oliver Planz
May 26, 2026
Clinical Scorecard: The Influence of Zapnometinib and Influenza A Virus on the HLA Class I Ligandome in Human Lung Adenocarcinoma Cells
At a Glance
Category Detail
Condition Influenza A Virus Infection Key Mechanisms MEK inhibition alters HLA class I antigen presentation and modulates immune responses. Target Population Patients with lung adenocarcinoma and influenza A virus infection. Care Setting Clinical research setting.
Key Highlights
Zapnometinib shows antiviral and immunomodulatory activity. HLA-I surface expression remains unchanged despite treatment. Significant modulation of HLA-I-presented peptides observed. Condition-specific enrichment in cellular pathways identified. Zapnometinib may enhance immune recognition through peptide presentation. Guideline-Based Recommendations
Diagnosis
Assess HLA-I expression and ligandome alterations in lung adenocarcinoma cells. Management
Consider zapnometinib as a host-directed antiviral strategy. Monitoring & Follow-up
Monitor changes in HLA-I ligandome and immune response markers. Risks
Potential for altered immune recognition and responses. Patient & Prescribing Data
Individuals with lung adenocarcinoma and influenza A virus infection.
Zapnometinib may reduce viral replication and modulate immune responses.
Clinical Best Practices
Utilize immunopeptidomic analyses to assess ligandome changes. Evaluate the impact of MEK inhibitors on immune recognition. Related Resources & Content
